Current state of hormone therapy in patients with metastatic breast cancer
Tarasenko T., Syvak L., Lyalkin S., Verovkina N., Martynyuk O., Bondar M.
Summary. Hormone-dependent, particularly estrogen receptor-positive tumors constitute the predominant part of breast malignancies. This article presents international recommendations for endocrine therapy that can be used in multiple lines of palliative therapy of metastatic hormone-dependent breast cancer in both premenopausal and postmenopausal women. The disruption of estrogen-mediated signaling pathway implementation within target cells is the main aim of hormonal therapy. Currently, three groups of drugs are clinically significant — selective estrogen receptor modulators, aromatase inhibitors and selective estrogen receptor degraders. The contemporary data of endocrine therapy options are offered here, considering patients clinical indicators, previous treatment and its outcome, drugs toxicity and its most expected adverse effects.
Leave a comment